Last reviewed · How we verify

NCT06848673: TBEye

Natural History of MTBI-related Convergence Insufficiency & Effectiveness of Vision Therapy for MTBI-related CI

Not yet recruiting Phase 2 Last updated 27 February 2025
What this trial tests

Phase 2 trial testing Office-Based Vergence/Accommodative Therapy with Movement (OBVAM) in Convergence Insufficiency in 100 participants. Not yet recruiting.

Timeline
1 November 2026
Primary endpoint
30 April 2028
30 September 2028

Quick facts

Lead sponsorSalus University
PhasePhase 2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment100
Start date1 November 2026
Primary completion30 April 2028
Estimated completion30 September 2028

Drugs / interventions tested

Conditions studied

Sponsor

Salus University

Who can join

Adults 18 to 35, any sex, with Convergence Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The design of this project is a pilot study, a type of feasibility study conducted in preparation for subsequent RCTs that will assess the effectiveness of office-based vergence/accommodative therapy with movement (OBVAM) for mTBI-related convergence insufficiency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Convergence Insufficiency

Currently open trials in the same condition.

Other Salus University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06848673.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing